AveXis to Use Intended Commercial GMP Product in SMA Type 2 Study
December 21, 2016 16:01 ET
|
AveXis
– SMA Type 2 study to initiate in Q2 2017 –– Streamlines development of Type 2 clinical data set –– Conference call and webcast December 21, at 4:30 p.m. EST – CHICAGO, Dec. 21, 2016 (GLOBE...
AveXis Reports Third Quarter 2016 Financial and Operating Results
November 10, 2016 16:01 ET
|
AveXis
– AVXS-101 demonstrated continued motor function improvement in ongoing study; majority of patients on proposed therapeutic dose achieved key developmental milestones – – Confirmed single-arm design...
AveXis to Present at Jefferies 2016 London Healthcare Conference
November 08, 2016 08:00 ET
|
AveXis
CHICAGO, Nov. 08, 2016 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening...
AveXis Announces Single-Arm Design for U.S. Pivotal Study of AVXS-101 in SMA Type 1 Patients
November 01, 2016 16:01 ET
|
AveXis
– Company provides update following receipt of FDA minutes from Type B meeting – – Conference call and webcast November 1 at 4:30 p.m. EDT – CHICAGO, Nov. 01, 2016 (GLOBE NEWSWIRE) --...
AveXis to Report Third Quarter 2016 Financial and Operating Results
October 31, 2016 08:00 ET
|
AveXis
CHICAGO, Oct. 31, 2016 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening...
AveXis to Host Webcast Update of Data from Ongoing Phase 1 Clinical Trial of AVXS-101 in Spinal Muscular Atrophy Type 1
October 10, 2016 07:00 ET
|
AveXis
-- Data, Including Developmental Milestones, as of September 15, 2016 as presented by Jerry Mendell, M.D. at the International Annual Congress of the World Muscle Society -- -- Webcast Today,...
AveXis Announces Pricing of Public Offering of Common Stock
September 08, 2016 07:25 ET
|
AveXis
CHICAGO, Sept. 08, 2016 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS) today announced the pricing of an underwritten public offering of 4,250,000 shares of its common stock, 3,960,145 shares of...
AveXis Announces Proposed Public Offering of 4,000,000 Shares of Common Stock
September 06, 2016 16:00 ET
|
AveXis
CHICAGO, Sept. 06, 2016 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS) today announced that it intends to offer and sell, subject to market conditions, 3,566,474 shares of its common stock in an...
AveXis Reports Second Quarter 2016 Financial and Operating Results and Interim Data from Ongoing Phase 1 Trial of AVXS-101 in Spinal Muscular Atrophy Type 1
August 11, 2016 16:01 ET
|
AveXis
-- Interim data through July 1 showed no “events” -- -- Continued motor function improvement with 25% of patients in the proposed therapeutic dose group in the normal range -- -- FDA requested...
AveXis to Report Second Quarter 2016 Financial and Operating Results and Interim Data from Ongoing Phase 1 Trial of AVXS-101 in Spinal Muscular Atrophy Type 1
August 02, 2016 08:00 ET
|
AveXis
CHICAGO, Aug. 02, 2016 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening...